Pharmacotherapy of Parkinson's Disease

Nyhet

From Basics to Practice

Häftad, Engelska, 2026

2 249 kr

Kommande

Pharmacotherapy of Parkinson's Disease: from Basics to Practice provides a comprehensive guide on the pharmacological treatment of Parkinson's Disease, offering students and clinicians a combination of foundational knowledge and advanced clinical insights. The book bridges theoretical concepts with real-world clinical scenarios and equips readers with the tools necessary to effectively manage Parkinson's Disease in practice. Offering a detailed review of symptoms, treatment gaps, and emerging therapies, this book delves into the pathogenesis the disease, along with dopaminergic treatments and management of motor and non-motor symptoms.

Providing updates on emerging therapies, including innovative treatment approaches, this book serves as a valuable reference for continuous learning and staying current with evolving practices and research in Parkinson's Disease management.

Reviews current pharmacological treatments for Parkinson's Disease, from foundational principles to advanced applications
Outlines the latest treatment protocols, therapeutic strategies, and emerging trends in Parkinson’s Disease pharmacotherapy
Provides detailed insights into how different drugs operate at the molecular and cellular levels, enhancing comprehension of PD pathophysiology and drug mechanisms
Presents case studies, clinical trial outcomes, and real-world applications, detailing practical insights applicable to both research and clinical practice

Produktinformation

Utgivningsdatum2026-09-01
Mått152 x 229 x undefined mm
Vikt450 g
FormatHäftad
SpråkEngelska
Antal sidor350
FörlagElsevier Science
ISBN9780443277023

Tillhör följande kategorier

Neurologi och klinisk neurofysiologi inom Medicin

Dr. Wael Mohamed Yousef Mohamed is Professor of Basic Medical Science at the International Islamic University Malaysia, with over 20 years of experience in translational brain research and longevity science. He earned his MD and MSc in Clinical Pharmacology from Meoufia Medical School, Egypt, and his PhD in Neuroscience from The Pennsylvania State University. His research focuses on aging-related neurodegeneration, particularly Alzheimer’s and Parkinson’s diseases, aiming to understand the biological mechanisms of aging and develop therapies to extend healthspan. Dr. Mohamed investigates how aging influences neurodegenerative processes and seeks targeted interventions to promote healthy longevity. He is a member of leading neuroscience societies, including the Society for Neuroscience. His prior editorial work with Elsevier includes titles on neurodegenerative and movement disorders, reflecting his expertise in aging, neurodegeneration, and longevity.

Section I: Introduction1. Parkinson’s Disease Pathogenesis: From Molecular Insights to Novel Therapies2. Cultural and Regional Considerations in Parkinson’s Pharmacotherapy3. The Tango of Parkinson’s Treatment: The Dance of Balance and Harmony4. Environmental Neurotoxins, Circadian Rhythms and Their Pharmacological Antagonists in Parkinson’s Disease5. Oral Bacteriome Dysbiosis and Mechanisms in Cognitive Impairment among Older People and Parkinson’s Disease: A Systematic ReviewSection II: L-DOPA and DOPAMINERGIC AGENTS6. Dopaminergic Treatments for Parkinson’s Disease: Seeing the Unseen7. Catechol-O-Methyl-Transferase (COMT) Inhibitors: Present Problems and Relevance of the New Ones8. D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents9. Non-Dopaminergic TherapiesSection III: EMERGING DRUGS AND TARGETS FOR PARKINSON'S DISEASE10. Management of Motor Symptoms11. Non-Motor Symptoms and Their Pharmacological Management12. Pharmacokinetics and Pharmacodynamics in Parkinson's Disease13. Clinical Case Studies and Practical Applications14. Epigenetic Modulators: Emerging Players in Parkinson’s PharmacotherapySection IV: FUTURE THERAPEUTIC POSSIBILITIES15. Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease16. Future Directions in Parkinson's Disease Pharmacotherapy17. Pioneering The Next Generation Of Therapies18. Genetic Therapies for Parkinson’s Disease: The Dawn of Precision Medicine19. The Gastrointestinal Microbiota and Parkinson’s Disease: What is known and what is still unknown.20. Artificial Intelligence and Machine Learning in Parkinson’s Drug Development21. Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to Pharmacotherapy in Parkinson’s DiseaseSection V: PHARMACOTHERAPY: HOPES AND HYPES22. Neuroprotective Therapies in Parkinson's Disease23. Polypharmacy and combination therapies in Parkinson’s Disease24. Repurposing Existing Drugs for Parkinson’s Disease Management25. Personalized Medicine andin Parkinson's Disease: Bridging Research and Practice26. Neuroprotective Diets and Their Synergy with PD Pharmacotherapy27. Natural products in the management of Parkinson’s disease in animal modelsSection VI: COGNITIVE NEHANCERS AND PD PHARMACOTHERAPY28. Cognitive Enhancers in Parkinson’s Disease29. Emerging Targets for Cognitive Enhancement30. Artificial Intelligence in PD Pharmacotherapy / Neurostimulation and AI-Augmented Cognitive Therapy31. Personalized Medicine for Cognitive Impairments in PD32. Ethical and Practical Challenges with Cognitive Enhancers33. Unani Pharmacotherapy in the Management of Parkinson’s disease: A Therapeutic Approach34. Music therapy and its synergy with pharmacotherapy in Parkinson’s Disease35. Summary and Conclusion